Ciprofloxacin/celecoxib

Ciprofloxacin/celecoxib

Combination of
Ciprofloxacin	Fluoroquinolone antibiotic
Celecoxib	Cyclooxygenase-2 inhibitor
Clinical data
Trade names	PrimeC
Legal status
Legal status	Investigational

PrimeC is a proprietary fixed-dose combination of ciprofloxacin and celecoxib, engineered as a synchronized extended-release, matrix-based formulation that enables optimized and coordinated delivery of both agents, despite their distinct physicochemical and pharmacokinetic properties. Developed by NeuroSense Therapeutics Ltd. for the treatment of ALS, PrimeC is designed to target multiple pathological pathways associated with the disease, including neuroinflammation, iron dysregulation, and miRNA dysregulation, and to reduce pathological TDP-43 accumulation in motor neuron cells. ^{[1] [2]}

References

1. Priyan, Vishnu (6 December 2023). "NeuroSense's trial of ALS drug meets primary and secondary endpoints". Clinical Trials Arena. Retrieved 7 December 2023.
2. Salomon-Zimri, Shiran; Pushett, Avital; Russek-Blum, Niva; Van Eijk, Ruben P. A.; Birman, Nurit; Abramovich, Beatrice; Eitan, Erez; Elgrart, Katya; Beaulieu, Danielle; Ennist, David L.; Berry, James D.; Paganoni, Sabrina; Shefner, Jeremy M.; Drory, Vivian E. (3 April 2023). "Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS". Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 24 (3–4): 263–271. doi: 10.1080/21678421.2022.2119868 . PMID   36106817.